Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06893510

Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia

Preeclampsia, affecting 2-8% of pregnancies globally, is a leading hypertensive disorder in pregnancy. It is clinically characterized by elevated blood pressure (≥140/90 mmHg) after the 20th gestational week, often accompanied by proteinuria and systemic complications such as thrombocytopenia, liver dysfunction, and cerebral symptoms. This condition poses significant risks for both maternal and fetal health, increasing the likelihood of organ damage, preterm birth, and long-term cardiovascular and neurodevelopmental complications. Non-pharmacological interventions, including relaxation techniques, have been explored for symptom management. Progressive muscle relaxation (PMR) has shown efficacy in reducing stress, anxiety, and blood pressure. Recently, virtual reality (VR)-based relaxation techniques have gained attention for enhancing stress relief and improving health outcomes. This study aims to compare the effects of VR-based PMR with in-person PMR on maternal and fetal outcomes in preeclamptic pregnancies.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Pre-eclampsia Female Urogenital Diseases and Pregnancy Complications Fetal Monitoring Hypertension, Pregnancy-Induced Maternal Health Pregnancy Complications Relaxation Urogenital Diseases Virtual Reality

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ümraniye Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location status: Recruiting

Location contact

Güzin Ünlü Suvari, M.Sc.

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospitalized with a diagnosis of preeclampsia.
  • Gestational age ≥26 weeks.
  • 18 years or older.
  • Singleton and viable pregnancy.
  • Willing to participate in the study voluntarily.

Exclusion criteria

  • Multiple pregnancy.
  • Pregnancy achieved through assisted reproductive technologies.
  • Hearing or vision impairment in the pregnant individual.
  • Fetal distress requiring emergency intervention.
  • HELLP Syndrome or Eclampsia.
  • History of vertigo.

Withdrawal Criteria:

  • Cases where live birth does not occur.
  • Participants who voluntarily withdraw from the study.
  • Participants whose general health condition deteriorates during the intervention.
  • Participants experiencing side effects from virtual reality headset use (e.g., dizziness, nausea, headache).
  • Participants who do not practice progressive muscle relaxation at least once a week after the intervention.

Treatment and study plan

Virtual Reality Based Progressive Muscle Relaxation

Other

Participants engage in progressive muscle relaxation exercises using a virtual reality headset that provides immersive visual and auditory relaxation content. Sessions are conducted under researcher supervision, followed by self-guided practice using an audio recording.

Face-to-Face Progressive Muscle Relaxation

Other

Participants practice progressive muscle relaxation exercises in a traditional face-to-face setting, guided by a researcher. Initial supervised sessions are complemented by self-guided practice using an audio recording.

Primary outcomes

  1. Descriptive Information Form

    Time frame: Day 1 (Baseline, Pre-Intervention)

    A researcher-developed questionnaire designed to collect sociodemographic and obstetric data based on the literature.

  2. Maternal-Fetal Outcomes Follow-up Form

    Time frame: Day 1 (Baseline, Pre-Intervention), Day 2 and 3 (Post-Intervention for intervention groups, routine monitoring for the control group)

    Tracked using a researcher-developed follow-up form, including maternal vital signs and Non-Stress Test (NST) parameters.

  3. Beck Anxiety Inventory (BAI)

    Time frame: Day 1 (Baseline, before intervention for intervention groups, before routine assessment for control group) and Day 3 (Post-intervention for intervention groups, after routine assessment for control group).

    Developed by Beck, Steer, Epstein, and Brown in 1988 and adapted into Turkish by Ulusoy et al. in 1998, this 21-item Likert-type scale measures anxiety levels. Each item is scored between 0 and 3, with total scores ranging from 0 to 63. Higher scores indicate higher levels of anxiety. The Turkish version has a Cronbach's alpha of 0.93, indicating high internal consistency. Factor analysis suggests two subscales: Subjective Symptoms and Somatic Symptoms.

  4. Prenatal Comfort Scale (PCS)

    Time frame: Day 1 (Baseline, before intervention for intervention groups, before routine assessment for control group) and Day 3 (Post-intervention for intervention groups, after routine assessment for control group).

    Originally developed by Takeishi et al. in 2011 in Japan and later revised by Nakamura et al. in 2015 to a 15-item version, this scale measures prenatal comfort across five subscales: Partner's Role in Fatherhood, Fetal Interaction, Social Support, Maternal Role Adaptation, and Awareness of Pregnancy Changes. The 6-point Likert-type scale ranges from 0 (strongly disagree) to 5 (strongly agree), with higher scores indicating higher comfort levels. The scale has a Cronbach's alpha of 0.95 in the original study and 0.82 in the Turkish adaptation.

  5. Heart Rate Variability (HRV) Measurement via Photoplethysmography (PPG)

    Time frame: Day 1 (Baseline, before the relaxation intervention) and Day 3 (Post-intervention, after the relaxation session).

    A non-invasive test used to assess physiological stress levels by measuring heart rate variability (HRV) through a photoplethysmography (PPG) sensor placed on the fingertip.

  6. Satisfaction Evaluation Form (VAS)

    Time frame: Day 3 (Post-Intervention)

    A researcher-developed form assessing participants' overall satisfaction with the intervention, perceived anxiety and stress reduction, and general experience. (only for intervention groups)

  7. Edinburgh Postpartum Depression Scale (EPDS)

    Time frame: Up to 4-6 weeks postpartum (via phone follow-up)

    eveloped by Cox et al. in 1987 and adapted into Turkish by Engindeniz et al. in 1996, this 10-item, 4-point Likert-type self-report scale assesses postpartum depression risk. Scores range from 0 to 30, with a cut-off point of 13. Internal consistency in the Turkish adaptation is 0.79, with a sensitivity of 0.84 and specificity of 0.88.

  8. Postpartum Evaluation Form

    Time frame: Up to 4-6 weeks postpartum (via phone follow-up)

    A researcher-developed form assessing delivery type, maternal and neonatal health parameters, and newborn evaluations based on literature

Study contacts

Contact information is provided by the study sponsor or research team.

Güzin Ünlü Suvari, M.Sc.

CONTACT

[email protected]

+902165004429

Sponsors and collaborators

Lead sponsor

Istanbul University - Cerrahpasa

Other

Registry information

Official study title

The Effect of Virtual Reality-Based and Face-to-Face Relaxation Programs on Maternal and Fetal Outcomes in Pregnant Women With Preeclampsia

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 25, 2025
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.